@article{CCO27599,
author = {Eiichiro Suzuki and John Bridgewater},
title = {Adjuvant therapy for resected gallbladder cancer},
journal = {Chinese Clinical Oncology},
volume = {8},
number = {4},
year = {2019},
keywords = {},
abstract = {Gallbladder cancer, one of the family of biliary tract cancers, has a poor prognosis. Adjuvant therapy comprising radiotherapy, chemotherapy plus radiation therapy and systemic chemotherapy may all play a role in improving survival. Most extant data on adjuvant therapy are retrospective studies or meta-analyses based on these studies. Recently, a phase III study demonstrated that capecitabine is a standard treatment option for biliary tract cancers, including gallbladder cancer. Ongoing studies investigating chemotherapy, novel surgical strategies, immunotherapy, molecular-targeted therapies using molecular profiling have been developed. This review summarises current status and future perspectives of adjuvant therapy for gallbladder cancer.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/27599}
}